Nuveen
XERS icon

Nuveen’s Xeris Biopharma Holdings XERS Stock Holding History

Nuveen’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.7M Buy
4,385,141
+1,468,543
+50% +$9.38M 0.01% 923
2026
Q1 		$16.9M Buy
2,916,598
+109,792
+4% +$728K ﹤0.01% 1238
2025
Q4 		$22M Sell
2,806,806
-21,068
-0.7% -$166K 0.01% 1091
2025
Q3 		$23M Buy
2,827,874
+227,432
+9% +$1.51M 0.01% 1057
2025
Q2 		$12.1M Buy
2,600,442
+370,935
+17% +$1.7M ﹤0.01% 1387
2025
Q1 		$12.2M Buy
2,229,507
+326,065
+17% +$1.32M ﹤0.01% 1432
2024
Q4 		$6.45M Buy
1,903,442
+228,380
+14% +$735K ﹤0.01% 1858
2024
Q3 		$4.77M Buy
1,675,062
+332,450
+25% +$854K ﹤0.01% 2012
2024
Q2 		$3.02M Sell
1,342,612
-247,890
-16% -$500K ﹤0.01% 2183
2024
Q1 		$3.52M Buy
1,590,502
+1,165,530
+274% +$3.02M ﹤0.01% 2141
2023
Q4 		$999K Sell
424,972
-287,725
-40% -$531K ﹤0.01% 2734
2023
Q3 		$1.33M Buy
712,697
+293,130
+70% +$672K ﹤0.01% 2459
2023
Q2 		$1.1M Sell
419,567
-1,849
-0.4% -$4.71K ﹤0.01% 2613
2023
Q1 		$687K Sell
421,416
-5,405
-1% -$6.77K ﹤0.01% 2725
2022
Q4 		$567K Sell
426,821
-23,362
-5% -$33K ﹤0.01% 2855
2022
Q3 		$702K Buy
450,183
+5,259
+1% +$8.7K ﹤0.01% 2872
2022
Q2 		$685K Buy
+444,924
New +$939K ﹤0.01% 2936
2021
Q2 		– Sell
-135,618
Closed -$612K – 3551
2021
Q1 		$612K Sell
135,618
-12,794
-9% -$69K ﹤0.01% 3052
2020
Q4 		$730K Sell
148,412
-374
-0.3% -$1.87K ﹤0.01% 2915
2020
Q3 		$883K Sell
148,786
-12,916
-8% -$51.6K ﹤0.01% 2734
2020
Q2 		$430K Sell
161,702
-14,592
-8% -$50.8K ﹤0.01% 2959
2020
Q1 		$344K Buy
176,294
+53,664
+44% +$231K ﹤0.01% 2899
2019
Q4 		$865K Sell
122,630
-1,117
-0.9% -$9.22K ﹤0.01% 2736
2019
Q3 		$1.22M Buy
123,747
+50,940
+70% +$572K ﹤0.01% 2615
2019
Q2 		$833K Buy
+72,807
New +$764K ﹤0.01% 2809

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen's XERS Position: Q2 2026 in Review

Nuveen increased its Xeris Biopharma Holdings (XERS) stake by 50% in Q2 2026, buying an estimated $9.38M and bringing the position to 4,385,141 shares worth $34.7M. The position accounts for 0.01% of the portfolio, ranked #923.

Nuveen first reported a position in XERS in Q2 2019 and has held it in 25 quarters since. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Nuveen held 4,385,141 shares of Xeris Biopharma Holdings worth $34.7M as of Q2 2026.
  • Nuveen bought 1,468,543 Xeris Biopharma Holdings shares in Q2 2026, an estimated $9.38M.
  • Xeris Biopharma Holdings made up 0.01% of Nuveen's portfolio in Q2 2026, its #923 holding.
  • Nuveen first reported a position in Xeris Biopharma Holdings in Q2 2019 and has held it in 25 quarters since.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.